RxDoctor Payments Data

Susan Bertrand, MD

Pain Medicine · Cary, NCNPI 1285627869

Payments from drug & device makers

$1,321in general payments, 2019–2025

Across 47 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$352
  • Boston Scientific$153
  • Scilex Pharmaceuticals Inc.$125
  • Collegium Pharmaceutical, Inc.$111
  • Nevro Corp.$105
  • GRT US Holding, Inc.$80
  • plus $396 from 13 others

What the payments were for

  • Food & beverage$1,321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,321 in reported general payments places this provider in the 25th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$79,898
Medicare patients
90
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen795$28,806
LinzessLinaclotide16$8,514
Xtampza ErOxycodone Myristate22$7,731
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen137$4,578
ZtlidoLidocaine12$4,444
Lidocaine37$3,764
Oxycodone Hcl165$3,587
Gabapentin258$3,197
Diclofenac Sodium56$2,876
Buprenorphine11$2,553
Tizanidine Hcl145$2,266
Tramadol Hcl70$1,912
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$1,550
Cyclobenzaprine Hcl108$1,023
Naloxone Hcl16$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$16$8,51416 claims
Collegium Pharmaceutical, Inc.Xtampza Er$111$7,73122 claims
Scilex Pharmaceuticals Inc.Ztlido$125$4,44412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →